Stock ACRV ACRIVON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-31 EDT 		5-day change 1st Jan Change
7.72 USD +1.98% Intraday chart for Acrivon Therapeutics, Inc. -2.89% +56.91%
05-14 Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 North American Morning Briefing : More Earnings -2- DJ

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
North American Morning Briefing : More Earnings -2-
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
Top Midday Gainers
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data
Acrivon Therapeutics Announces Private Placement of 8.2 Million Shares; Shares Surge
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell
Top Premarket Gainers
Acrivon Therapeutics Announces $130 Million Private Placement Financing
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACRV Stock
  4. News Acrivon Therapeutics, Inc.
  5. Other languages